We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Bioinformatics Used to Detect Rogue Use of Synthetic Biology

By LabMedica International staff writers
Posted on 19 Aug 2010
A team of American and French students is using bioinformatics to implement federal guidance on synthetic genomics. More...
The students' work will help gene synthesis companies and their customers detect the possible use of manufactured DNA as harmful agents for bioterrorism.

Synthetic biology offers huge potential for practical applications in medicine, energy production, agriculture, and other areas. For a couple of thousand [U.S.] dollars, it is now possible to design custom DNA sequences the size of a viral genome, order these sequences from a DNA manufacturer, and receive the DNA in the mail within a few weeks. Experts are concerned, however, about the potential misuse of these emerging technologies and that is where the student's project could play a key role in preventing synthetic biology malpractice.

The students involved in the project were from ENSIMAG (Grenoble, France), an engineering school, and Virginia Polytechnic Institute and State University (Virginia Tech; Blacksburg, USA). Dr. Jean Peccoud, associate professor at the Virginia Bioinformatics Institute (VBI) at Virginia Tech and leader of Virginia Tech's iGEM initiatives, said, "The students have taken great strides in implementing different possible interpretations of the federal recommendations. Their work characterizes the relationship between the computational cost of the screen and its sensitivity. This independent scientific analysis will identify practical solutions compatible with the operational constraints of commercial operators and refine policies aimed at protecting the nation without undermining its competitiveness.”

Algorithms under development assess how similar a specific DNA sequence is to entries in the U.S. Centers for Disease Control and Prevention's (Atlanta, GA, USA) Select Agent and Toxin List. The keyword lists help to track down matches and allow for continual fine-tuning of the effectiveness of each search. The students are compiling a database of test cases that allows them to estimate the performance of different screening strategies.

Edward You, supervisory special agent in the U.S. Federal Bureau of Investigation's (FBI) Weapons of Mass Destruction Directorate, had the opportunity to visit VBI on June 4, 2010, and gave a seminar entitled "Biosecurity: The roles and responsibilities of academia and law enforcement.” During his visit, he met with some of the students working on the iGEM project. "The students should be commended for tackling a real-life problem directly related to national security needs,” said Agent You. "By working on this significant project, they are actively participating in the development of responsible practice for this transformative science, which is exactly what the government of this country wants to encourage. It is very promising to see undergraduate students at iGEM engage their peers in thinking about biosecurity. The groundbreaking work of this international team impacts the safety of people around the globe.”

The final results of the Virginia Tech-ENSIMAG biosecurity team's analyses will be presented November 2010 at the International Genetically Engineered Machines (iGEM) synthetic biology competition organized by the Massachusetts Institute of Technology (Cambridge, MA, USA).

Related Links:
ENSIMAG
Virginia Polytechnic Institute and State University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.